Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
- Registration Number
- NCT02018172
- Lead Sponsor
- Ferring Pharmaceuticals
- Brief Summary
The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 3
-
Patient with growth hormone deficiency,
- Diagnosis of growth hormone deficiency proven by appropriate exploration
- Size ≤ -2 Standard Deviation (SD) according to the French references
- Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year
-
Growth deficiency due to Turner's syndrome
- Turner's syndrome confirmed by a karyotype
- Patient's size ≤ -2 SD according to the French references
- Bone age < 12 years
-
Patient who require a minimum of 18 months of treatment.
- There are no exclusion criteria except the contraindication for Zomacton® 10 mg
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Zomacton® treatment with Zomajet® Vision X device somatropin -
- Primary Outcome Measures
Name Time Method Rate of overall treatment adherence Up to 18 months Ratio between actual duration of administration and total duration recommended by physician
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôpital des Enfants, CHU de Toulouse
🇫🇷Toulouse, France